Myofascial pain and fibromyalgia: a 2015 narrative update · Lab study · 2015
What do early studies say about shockwave for myofascial pain and fibromyalgia?
This review explains what trigger points and tender points are and lists six early studies of shockwave for muscle pain, most with favourable conclusions. It gives no figures for how much people improved. Its fibromyalgia findings come from the authors’ own trial, shared only at a conference.
Explores how shockwave works- studies of myofascial pain listed
- 6
- people in the authors' fibromyalgia trial
- 24
- conditions: myofascial pain and fibromyalgia
- 2
Good to know: A narrative review of early studies.
Ramon S, Gleitz M, Hernandez L, et al. Int J Surg, 2015 · Read the paper ↗
The treatment
- Regimens in summarized studies
- Focused devices (piezoelectric, electrohydraulic, electromagnetic) at 0.04–0.26 mJ/mm² and radial devices, 800–3,000 pulses, 3–12 sessions, as listed in Table 2; parameters are incompletely reported for some studies.
- Fibromyalgia trial regimen
- Radial ESWT, 5 sessions: 500 pulses at 1.5 bar and 15 Hz, 1,000 at 2 bar and 8 Hz, then 500 at 1.5 bar and 15 Hz on each of the 3 most painful points. Placebo: same pulse count at 1.5 bar through a soft rubber cap held off the skin.
- Authors' suggested ranges (opinion)
- Focused: 1,000–2,000 pulses, 4 Hz, 0.1 mJ/mm² (0.05–0.35), 1–3 sessions; radial: 1,000 pulses, 1–2 bar, 6–10 Hz, 3–5 sessions; weekly; no local anesthesia; with supervised exercise. Untested as a package.
Who took part
No new patients. Six earlier studies, mostly of neck and shoulder trigger points, and a 24-person fibromyalgia trial by the authors.
Side effects
The authors say their fibromyalgia trial had no side effects.
All the numbers and the full appraisal
What the full paper reports.
No new patient cohort. A narrative review that summarizes six myofascial pain studies in Table 2 (mostly trapezius studies; group sizes are given only for Müller-Ehrenberg 2005 and Jeon 2012, 30 patients each, and the plantar fasciitis trial, 40) and describes the authors' own 24-patient fibromyalgia trial presented at a 2014 congress.
Myofascial pain studies summarized1 reported outcome
Myofascial pain studies summarized
Qualitative finding
Table 2: Müller-Ehrenberg 2005 (focused piezoelectric, VAS decrease at 3 months; the text adds pain relief in 95% of 30 patients); Jeon 2012 (focused, "as effective as" TENS plus trigger-point injection); Ji 2012 (focused, better than placebo on VAS, pain threshold and Roles and Maudsley); Cho 2012 (radial ESWT plus stabilization exercise; the review reports better pain and function with the combined therapy but does not name the comparison group); Moghtaderi 2014 (adding gastrocnemius–soleus trigger-point treatment in plantar fasciitis, 40 patients); Gür 2014 (three sessions better than one). No effect sizes, intervals or denominators are given.
Analysis details and source
Descriptive summaries copied from the review; the review does not appraise or pool these studies. Jeon 2012 and Ji 2012 are analysed separately in this library.
Fibromyalgia trial described by the authors1 reported outcome
Fibromyalgia trial described by the authors
Qualitative finding
24 fibromyalgia patients randomized to five sessions of radial ESWT (2,000 pulses on each of the 3 most painful points) or placebo; the authors report significant improvement in local VAS pain, algometry, Roles and Maudsley, FIQ and SF-36 pain at 3 months with no side effects. Arm sizes, values, between-group tests and comparisons with placebo are not reported.
Analysis details and source
Source is the authors' own presentation at the 2014 ISMST congress (reference 43), not a peer-reviewed full report. Whether "significant improvement" refers to within-group change or a difference from placebo is not stated.
Authors' suggested treatment ranges1 reported outcome
Authors' suggested treatment ranges
Qualitative finding
The authors propose low-to-medium energy ranges for myofascial pain and radial treatment of tender or trigger points in fibromyalgia, always with supervised exercise, and conclude that fibromyalgia "can no longer be considered an exclusion criterion" for ESWT. These ranges are opinion and were not tested as a package in the cited studies.
Analysis details and source
Reported to describe the source, not as a recommendation.
How treatment was delivered
Focused devices (piezoelectric, electrohydraulic, electromagnetic) at 0.04–0.26 mJ/mm² and radial devices, 800–3,000 pulses, 3–12 sessions, as listed in Table 2; parameters are incompletely reported for some studies.
Radial ESWT, 5 sessions: 500 pulses at 1.5 bar and 15 Hz, 1,000 at 2 bar and 8 Hz, then 500 at 1.5 bar and 15 Hz on each of the 3 most painful points. Placebo: same pulse count at 1.5 bar through a soft rubber cap held off the skin.
Focused: 1,000–2,000 pulses, 4 Hz, 0.1 mJ/mm² (0.05–0.35), 1–3 sessions; radial: 1,000 pulses, 1–2 bar, 6–10 Hz, 3–5 sessions; weekly; no local anesthesia; with supervised exercise. Untested as a package.
The review presents no systematic harms data. It states that the authors' fibromyalgia trial had no side effects, without event definitions or counts; harms in the other summarized studies are not reported.
Author-reported: studies with larger series of patients and better methods are needed to confirm the results; fibromyalgia efficacy is called controversial in the highlights.
Extractor: narrative review with no stated search, selection criteria, risk-of-bias or certainty assessment; included studies are summarized by their authors' conclusions, with no effect sizes, so selective citation cannot be excluded.
Internal inconsistencies: the text says "as yet no literature is available on ESWT and FM" and then reports the authors' own trial; Ji 2012 is 700 + 300 impulses in the text but 1,000 pulses in Table 2; Müller-Ehrenberg 2005 is 800 impulses in the text but 800–1,000 in Table 2; radial pulse duration is 0.2–0.5 ms in the text but about 0.2–5 ms in Figure 3. Moghtaderi 2014 concerns plantar fasciitis, not a primary myofascial pain population.
Extractor: the highlights state that "ESWT is an efficient tool for the treatment of myofascial pain syndrome", a stronger claim than the cited small, mostly short-term studies can support. The fibromyalgia conclusion relies on the authors' own congress abstract. Funding: none received. Conflicts: none declared.
Findings checked against the full source by a separate automated reviewer.
Limitations noted by the reviewers
- Author-reported: studies with larger series of patients and better methods are needed to confirm the results; fibromyalgia efficacy is called controversial in the highlights.
- Extractor: narrative review with no stated search, selection criteria, risk-of-bias or certainty assessment; included studies are summarized by their authors' conclusions, with no effect sizes, so selective citation cannot be excluded.
- Internal inconsistencies: the text says "as yet no literature is available on ESWT and FM" and then reports the authors' own trial; Ji 2012 is 700 + 300 impulses in the text but 1,000 pulses in Table 2; Müller-Ehrenberg 2005 is 800 impulses in the text but 800–1,000 in Table 2; radial pulse duration is 0.2–0.5 ms in the text but about 0.2–5 ms in Figure 3. Moghtaderi 2014 concerns plantar fasciitis, not a primary myofascial pain population.
- Extractor: the highlights state that "ESWT is an efficient tool for the treatment of myofascial pain syndrome", a stronger claim than the cited small, mostly short-term studies can support. The fibromyalgia conclusion relies on the authors' own congress abstract. Funding: none received. Conflicts: none declared.
Source-linked critical reading
Narrative review
This review explains what trigger points and tender points are and lists a handful of small early studies of shockwaves for muscle pain, most with favourable conclusions. It does not measure how much benefit to expect, and its fibromyalgia claims rest on the authors' own unpublished data.
What did published work up to 2015 say about extracorporeal shockwave treatment for myofascial pain syndrome and fibromyalgia, and how do the authors suggest applying it?
Narrative review without a described search, selection criteria or quality appraisal. It combines background on trigger-point theory, a six-study evidence table and the authors' own fibromyalgia trial reported at a congress.
No new patient cohort. A narrative review that summarizes six myofascial pain studies in Table 2 (mostly trapezius studies; group sizes are given only for Müller-Ehrenberg 2005 and Jeon 2012, 30 patients each, and the plantar fasciitis trial, 40) and describes the authors' own 24-patient fibromyalgia trial presented at a 2014 congress.
Focused (piezoelectric, electrohydraulic, electromagnetic) and radial shockwaves to trigger points, taut bands or tender points; doses in the summarized studies ranged from 0.04 to 0.26 mJ/mm² and 3 to 12 sessions, with some parameters missing.
Comparators in the summarized studies were TENS plus trigger-point injection, placebo shockwaves, a comparison group the review does not specify (Cho 2012), plantar-fascia-only treatment and one versus three sessions; the fibromyalgia trial used a placebo applicator with a rubber cap. The review itself makes no new comparison.
Outcomes are those of the summarized studies (VAS, pain threshold, McGill, Roles and Maudsley, functional scores) and, for the fibromyalgia trial, VAS, algometry, FIQ and SF-36 pain at 3 months.
Table 2 lists six studies with favourable conclusions for focused or radial ESWT in myofascial pain, summarized in one line each without effect sizes. For fibromyalgia, the authors describe their own 24-patient randomized trial (5 radial sessions versus placebo) as improving local pain, algometry, Roles and Maudsley, FIQ and SF-36 pain at 3 months without side effects, but give no numbers; the text also states that no literature on ESWT and fibromyalgia exists.
The review presents no systematic harms data. It states that the authors' fibromyalgia trial had no side effects, without event definitions or counts; harms in the other summarized studies are not reported.
No search strategy, inclusion criteria or risk-of-bias appraisal; the six studies in Table 2 are summarized only by their authors' conclusions. The fibromyalgia evidence is the authors' own congress abstract, presented without data, alongside a statement that no literature exists. Text and Table 2 differ on several doses. The highlights call ESWT "an efficient tool" for myofascial pain, which these small studies cannot establish. No funding; no conflicts declared.
Useful for understanding how trigger points, taut bands and tender points are defined and how early shockwave studies were done. It cannot indicate the size of benefit, a preferred device or dose, or whether shockwaves help people with fibromyalgia.
A systematic review with a reproducible search and risk-of-bias appraisal, and a peer-reviewed full report of the fibromyalgia trial with arm sizes, between-group estimates and harms.
Read the original article.
Update on the efficacy of extracorporeal shockwave treatment for myofascial pain syndrome and fibromyalgia.
Ramon S, Gleitz M, Hernandez L, Romero LD. · Int J Surg · 2015
Open the publication record or available full-text files.
Checked against the full paper · Clinical review: Dr. Marcus Yu Bin Pai, · How we review →